Mecapegfilgrastim
Phase 2Protein / enzyme
Mecapegfilgrastim is one of 100 small molecule programs targeting Neutropenia. It is currently in Phase 2.
3
Indications
6
Total Trials
5
Active Trials
99
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tykerb
GSKPreclinical
Prolia
AmgenPreclinical
MS Contin
Merck & Co.Preclinical
Mecapegfilgrastim
TTianjin Medical University Cancer Institute and Hospital
Phase 2
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer2 trials
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05463601·132 enrolled
Esophagitis1 trial
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT04171986·93 enrolled
Neutropenia1 trial
Chemoradiotherapy1 trial
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Recruiting·—·Phase 2·NCT07205536·30 enrolled
Neoadjuvant Therapy1 trial
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06684158·70 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mecapegfilgrastim. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details